[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Kadin ME: Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders. Oncology (Williston Park); 2009 Nov 30;23(13):1158-64
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders.
  • Primary cutaneous CD30+ T-cell lymphoproliferative disorders (PCLPDs) are the second most common type of cutaneous T-cell lymphoma.
  • These disorders comprise a spectrum of clinically benign lymphomatoidpapulosis (LyP) and primary cutaneous anaplastic large-cell lymphoma (ALCL).
  • The peak incidence of LyP is in the 5th decade of life, and the incidence of primary cutaneous ALCL peaks in the 6th decade, but children are also affected.
  • Both LyP and primary cutaneous ALCL have an excellent prognosis.
  • However, LyP is associated with development of malignant lymphoma (mycosis fungoides, Hodgkin lymphoma, or ALCL) in 20% of cases, and also with an increased risk of non-lymphoid cancers.
  • Primary cutaneous ALCL must be distinguished from secondary skin lesions in systemic ALCL, which confer a poor prognosis.
  • Correlation of clinical findings with histopathology and immunopathology (stains for ALK kinase, epithelial membrane antigen, and cutaneous lymphocyte antigen) are important to achieve a correct diagnosis.
  • Low-dose methotrexate (10-25 mg weekly) is the most effective therapy for PCLPD but is usually reserved for aggressive cases of LyP and multifocal lesions of cutaneous ALCL Many patients with LyP can be followed expectantly, with special attention to changes in character of the skin lesions or development of lymphadenopathy.
  • Patients with localized cutaneous ALCL can be treated with irradiation.
  • Extracutaneous spread of disease is an indication for multiagent chemotherapy.
  • Other treatment alternatives are discussed.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Lymphoma, Primary Cutaneous Anaplastic Large Cell / drug therapy. Methotrexate / administration & dosage. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043465.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20RR018757
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 32
  •  go-up   go-down


2. Copur MS, Deshpande A, Mleczko K, Norvell M, Hrnicek GJ, Woodward S, Frankforter S, Mandolfo N, Fu K, Chan WC: Full clinical recovery after topical acyclovir treatment of Epstein-Barr virus associated cutaneous B-cell lymphoma in patient with mycosis fungoides. Croat Med J; 2005 Jun;46(3):458-62
Hazardous Substances Data Bank. ACYCLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Full clinical recovery after topical acyclovir treatment of Epstein-Barr virus associated cutaneous B-cell lymphoma in patient with mycosis fungoides.
  • Primary cutaneous T- and B-cell lymphomas are a heterogeneous group of diseases with varied clinical presentations and prognosis.
  • Cutaneous B-cell and T-cell lymphomas are seldom found together in the same patient.
  • Here we report a rare case of mycosis fungoides variant of a cutaneous T-cell lymphoma (CTCL) which later developed Epstein-Barr virus (EBV) associated cutaneous B-cell lymphoproliferative disorder.
  • Histopathology and immunophenotyping of her tumor from the right breast nodule revealed a T-cell lymphoma consistent with mycosis fungoides.
  • After progression of her mycosis fungoides with worsening diffuse skin lesions on this regimen, her treatments were changed to oral bexarotene with an initial partial response followed by stable disease.
  • Three years from her initial presentation, she developed ulcerated cauliflower-like nodules on her forehead.
  • Skin lesions gradually diminished and totally disappeared after four weeks of topical acyclovir treatment.
  • Bexarotene treatment was continued for another year until the mycosis fungoides progressed and became wide spread causing her death four and a half years after the initial diagnosis.
  • The coexistence of two cutaneous non-Hodgkin lymphomas of different lineage in the same patient and the complete clinical response of EBV-related B-cell cutaneous component to topical acyclovir makes this rare case particularly interesting.
  • [MeSH-major] Acyclovir / therapeutic use. Antiviral Agents / therapeutic use. Epstein-Barr Virus Infections / drug therapy. Lymphoma, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15861527.001).
  • [ISSN] 0353-9504
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antiviral Agents; X4HES1O11F / Acyclovir
  •  go-up   go-down


3. Yaich S, Zagdane S, Charfeddine K, Hssairi D, Hachicha J: Simultaneous Hodgkin's disease and Kaposi sarcoma in a renal transplant recipient. Saudi J Kidney Dis Transpl; 2010 Mar;21(2):306-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous Hodgkin's disease and Kaposi sarcoma in a renal transplant recipient.
  • She received induction therapy with antithymoglobulin (ATG) as standard protocol and maintained on immunosuppressive treatment of cyclosporine A, mycophenolate mofetil (MMF), and prednisone.
  • Cutaneous Kaposi's sarcoma and a Hodgkin disease were diagnosed.
  • She also received a poly-chemotherapy associated with 4 courses of rituximab.
  • [MeSH-major] Hodgkin Disease / etiology. Immunosuppressive Agents / adverse effects. Kidney Transplantation / adverse effects. Neoplasms, Multiple Primary. Sarcoma, Kaposi / etiology. Skin Neoplasms / etiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Therapy, Combination. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20228518.001).
  • [ISSN] 1319-2442
  • [Journal-full-title] Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
  • [ISO-abbreviation] Saudi J Kidney Dis Transpl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


Advertisement
4. Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B: CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood; 2000 Dec 1;96(12):3681-95
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.
  • Anaplastic large cell lymphoma (ALCL) represents a generally recognized group of large cell lymphomas.
  • With the use of molecular and clinical criteria, 3 entities of ALCL have been identified: primary systemic anaplastic lymphoma kinase (ALK)(+) ALCL, primary systemic ALK(-) ALCL, and primary cutaneous ALCL.
  • ALK(+) ALCL predominantly affects young male patients and, if treated with chemotherapy, has a favorable prognosis.
  • It shows a broad morphologic spectrum, with the "common type," the small cell variant, and the lymphohistiocytic variant being most commonly observed.
  • The morphology and the immunophenotype of primary cutaneous ALCL show an overlap with that of lymphomatoid papulosis.
  • In contrast, large B-cell lymphomas with anaplastic morphology are believed to represent not a separate entity but a morphologic variant of diffuse large B-cell lymphoma.
  • Malignant lymphomas with morphologic features of both Hodgkin disease and ALCL have formerly been classified as Hodgkin-like ALCL.
  • Recent immunohistologic studies, however, suggest that ALCLs Hodgkin-like represent either cases of tumor cell-rich classic Hodgkin disease or (less commonly) ALK(+) ALCL or ALK(-) ALCL. (Blood.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / genetics
  • [MeSH-minor] Gene Rearrangement. Hodgkin Disease. Humans. Immunophenotyping. Nuclear Proteins / genetics. Protein-Tyrosine Kinases / genetics. Receptor Protein-Tyrosine Kinases. Translocation, Genetic

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11090048.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Number-of-references] 157
  •  go-up   go-down


5. Sréter L: [Therapy in Hodgkin disease and non-Hodgkin lymphomas]. Orv Hetil; 2009 Apr 5;150(14):651-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy in Hodgkin disease and non-Hodgkin lymphomas].
  • [Transliterated title] A Hodgkin- és a non-Hodgkin-lymphomák kezelése.
  • The therapy of malignant lymphoproliferative diseases has changed many times in recent years.
  • Treatment strategy of Hodgkin's disease is now based on risk adaptation, including not only the results of pretreatment diagnostic and prognostic factors but also the repeated PET/CT (restaging) made in the early treatment period.
  • Possible reduction of irradiation therapy may contribute to lower the risk of secondary tumors, which are common late complications of radiochemotherapy.
  • Autologous stem cell transplantation is the therapy of choice in chemosensitive relapsing patients.
  • The complete remission rate today in Hodgkin's disease is around 85%.
  • In the heterogenic group of Non-Hodgkin Lymphomas, progression of indolent lymphomas (CLL, multiple myeloma, hairy cell leukemia, cutaneous lymphomas, etc.) is slow in case of natural course.
  • Their therapy is mostly palliative and complete remission with the latest treatment modalities is not possible.
  • Aggressive lymphomas are characterized with rapid progression and early death without treatment.Most of them respond to chemotherapy and irradiation.With an adequate therapy, 60-70% of patients reach complete remission (CR) and 40-50% of them remain in remission.
  • Using immune- and radioimmune therapy in indolent and aggressive NHL groups gives possibility to influence G0 tumor cells as well.
  • Their use in combination with classic chemotherapy leads to more complete remissions and better therapy results.
  • The introduction of routine PET/CT made the first and repeated staging of NHL more precise and contributed to more effective treatment.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Neoplasms, Second Primary / prevention & control
  • [MeSH-minor] Disease Progression. Humans. Leukemia, Hairy Cell / diagnosis. Leukemia, Hairy Cell / therapy. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Multiple Myeloma / diagnosis. Multiple Myeloma / therapy. Neoplasm Staging. Positron-Emission Tomography. Remission Induction. Stem Cell Transplantation. Tomography, X-Ray Computed. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318337.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


6. Khalifeh I, Hughey LC, Huang CC, Reddy VV, Sellheyer K: Solitary plaque on the scalp as a primary manifestation of Hodgkin lymphoma: a case report and review of the literature. J Cutan Pathol; 2009 Oct;36 Suppl 1:80-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary plaque on the scalp as a primary manifestation of Hodgkin lymphoma: a case report and review of the literature.
  • Cutaneous Hodgkin lymphoma is infrequent and typically occurs after extensive involvement of the lymph nodes.
  • The condition decreased significantly in incidence in the past two decades, likely owing to the new treatment protocols composed of chemotherapy, radiotherapy and stem cell transplantation.
  • Nevertheless, recognition of this uncommon but significant disease manifestation is important from a prognostic and therapeutic perspective.
  • We are sharing a recent case of Hodgkin lymphoma where the primary presentation appeared as a solitary plaque on the left side of the occipital scalp, clinically suspected to represent a ruptured follicular cyst.
  • Histological assessment revealed Hodgkin lymphoma affecting the skin.
  • However, two enlarged lymph nodes were identified in the mediastinum and were positron emission tomography avid.
  • The patient underwent systemic treatment without further histopathological examination of these two lymph nodes.
  • Not being clear if these enlarged two lymph nodes were related to his cutaneous disease or not, we cannot be sure if the patient was afflicted either by primary cutaneous Hodgkin lymphoma or by secondary cutaneous involvement because of hematogenous spread.
  • In either case, primary or secondary cutaneous Hodgkin disease is an extreme rarity.
  • [MeSH-major] Hodgkin Disease / pathology. Scalp / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Immunohistochemistry. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19775396.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 32
  •  go-up   go-down


7. Mukesh M, Shuttleworth D, Murray P: Primary cutaneous Hodgkin's lymphoma. Clin Exp Dermatol; 2009 Dec;34(8):e673-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous Hodgkin's lymphoma.
  • Cutaneous involvement in Hodgkin's lymphoma is an uncommon but well-recognized condition that usually occurs with advanced-stage disease.
  • Primary cutaneous Hodgkin's disease (PCHD) is exceedingly rare, with only a few reported cases.
  • We report a case of a man treated with combination systemic chemotherapy for PCHD, and review the available literature.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Bleomycin / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817768.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  • [Number-of-references] 10
  •  go-up   go-down


8. Nieto Y, Shpall EJ, Bearman SI, McSweeney PA, Cagnoni PJ, Matthes S, Gustafson D, Long M, Barón AE, Jones RB: Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies. Biol Blood Marrow Transplant; 2005 Apr;11(4):297-306
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifty-nine patients with advanced refractory malignancy (32 breast cancer, 10 non-Hodgkin lymphoma, 6 germ cell tumors, 4 Hodgkin disease, 4 ovarian cancer, 2 sarcoma, and 1 unknown primary adenocarcinoma) with a median of 3 prior chemotherapy regimens and a median of 3 organs involved were enrolled.
  • Treatment included docetaxel (150-550 mg/m2 infused over 2 hours on day -6), melphalan (150-165 mg/m2 infused over 15 minutes from day -5 to -3), and carboplatin (1000-1300 mg/m2 as a 72-hour continuous infusion from day -5).
  • The remaining 25 patients presented the following extramedullary toxicity profile, which was manageable and largely reversible: stomatitis, myoarthralgias, peripheral neuropathy, gastrointestinal and cutaneous toxicities, and syndrome of inappropriate antidiuretic hormone secretion.
  • The response rate among 38 patients with measurable disease was 95%, with 47% complete responses.
  • The notable activity of this regimen in treatment-refractory patients warrants its further evaluation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15812395.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; Q41OR9510P / Melphalan
  •  go-up   go-down


9. Gautschi O, Blumenthal N, Streit M, Solenthaler M, Hunziker T, Zenhäusern R: Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H). Eur J Haematol; 2004 Jan;72(1):61-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).
  • INTRODUCTION: Sézary syndrome (SS) is a cutaneous T-cell lymphoma characterized by erythroderma, lymphadenopathy and circulating atypical T cells.
  • Median survival after diagnosis is 10 yr, with chemotherapy resistance being a major problem in advanced disease.
  • Alemtuzumab is approved for relapsing chronic B-cell leukemia and seems to be active also in T-cell lymphomas such as T-cell prolymphocytic lymphoma, SS and mycosis fungiodes.
  • The disease had not responded to PUVA/interferon-alpha and progressed on chemotherapy with CHOP, 2-CDA, vinorelbine, etoposide and liposomal doxorubicin.
  • Following treatment with alemtuzumab (30 mg i.v. three times per week for 10 wk), itching resolved rapidly and an almost complete remission was achieved within 3 months after starting this treatment.
  • At 12-month follow up, no disease progression was present.
  • CONCLUSION: In accordance with previous data, this single case underlines the potent activity of alemtuzumab in advanced, chemotherapy-refractory SS.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Neoplasms, Second Primary / drug therapy. Sezary Syndrome / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance. Hodgkin Disease / drug therapy. Humans. Male

  • Genetic Alliance. consumer health - Sezary syndrome.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14962265.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


10. Schad K, Baumann Conzett K, Cozzio A: [Cutaneous lymphomas]. Ther Umsch; 2010 Sep;67(9):453-64
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous lymphomas].
  • Cutaneous lymphomas are a heterogenous group of lymphoproliferative disorders of the T- and B-lymphocytes with a low incidence of approximately 1:100000/year.
  • They belong to the Non-Hodgkin lymphoma.
  • The skin is the second most abundant site of extranodal lymphoma formation (after the GI tract).
  • The new WHO/EORTC classification of cutaneous T- and B-cell lymphomas provides a widely accepted nomenclature for primary cutaneous lymphomas based primarily on clinical, but also on histologic, cytologic and molecular features.
  • The clear distinction of primary cutaneous from secondary cutaneous lymphoma will also be important to prevent overtreatment of the frequently benign primary cutaneous lymphoma.
  • Treatment of primary cutaneous lymphoma is skin-directed in early disease stages, and uses as systemic approach in advanced stages.
  • Skin-directed therapies encompass UV-light treatment such as UVB311nm, or PUVA, topical steroids class III and IV, or bexaroten gel.
  • Systemic treatment options may be immunomodulatory, such as treatment with interferon alpha injection, or biologic response modifiers such as bexarotene.
  • We recommend that advanced stages of cutaneous lymphoma should be treated in centers that offer clinical studies in this field, because prognosis of late stages is still dismal and there is so far no therapeutic approach that has led to an increase in overall survival.
  • Hence, inclusion of patients in prospective controlled clinical studies should always be considered in patients with primary cutaneous lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / diagnosis. Lymphoma, T-Cell, Cutaneous / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Humans. Interferon-alpha / therapeutic use. Mycosis Fungoides / diagnosis. Mycosis Fungoides / drug therapy. Mycosis Fungoides / pathology. Mycosis Fungoides / radiotherapy. Neoplasm Staging. PUVA Therapy. Prognosis. Radiotherapy, Adjuvant. Skin / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20806174.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  •  go-up   go-down


11. Koh LP, Wong LC, Ng SB, Poon ML, Low JJ: Primary cutaneous anaplastic large cell lymphoma of the vulva: a typical cutaneous lesion with an 'atypical' presenting site. Int J Hematol; 2009 Oct;90(3):388-91
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous anaplastic large cell lymphoma of the vulva: a typical cutaneous lesion with an 'atypical' presenting site.
  • Non-Hodgkin lymphoma of vulva is exceedingly rare and it often poses a diagnostic challenge if their existence is not suspected.
  • We report a patient who has primary cutaneous anaplastic large cell (C-ALCL) with an unusual presentation as a vulvar ulcer.
  • She received a brief course of chemotherapy followed by local irradiation and has remained disease-free more than a year from the time of diagnosis.
  • To our knowledge, primary C-ALCL involving the vulva has never been reported.
  • Despite its typical cutaneous manifestation of C-ALCL, the uncommon presenting site of this entity warrants recognition because of its prognostic and therapeutic implication.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Skin / pathology. Skin Neoplasms / pathology. Vulvar Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Positron-Emission Tomography. Prognosis


12. Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Turturro F, Walker PL, Fayad L: Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol; 2007 Feb;136(3):439-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
  • This phase II study evaluated the safety and efficacy of denileukin diftitox, an interleukin-2-diphtheria toxin fusion protein, in relapsed/refractory T-cell non-Hodgkin lymphoma (T-NHL), excluding cutaneous T-cell lymphoma.
  • Tumour staging was performed every two cycles and the primary endpoint was the objective response rate [complete response (CR) + partial response (PR)].
  • For 27 patients enrolled, median age: 55 years (range 26-80 years), 70.4% male, and mean prior therapies: 2.5 (range 1-6).
  • Objective responses (six CRs, seven PRs) were achieved in 13 patients (48.1%), stable disease in eight (29.6%) and six (22.2%) had progressive disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Diphtheria Toxin / therapeutic use. Interleukin-2 / therapeutic use. Lymphoma, T-Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Drug Administration Schedule. Drug Resistance, Neoplasm. Fatigue. Female. Humans. Interleukin-2 Receptor alpha Subunit / analysis. Male. Middle Aged. Neoplasm Staging. Recombinant Fusion Proteins / adverse effects. Recombinant Fusion Proteins / therapeutic use. Transaminases / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17233846.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox; EC 2.6.1.- / Transaminases
  •  go-up   go-down


13. Visco C, Medeiros LJ, Jones D, Smith T, Rodriguez MA, McLaughlin P, Romaguera J, Cabanillas F, Sarris AH: Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement. Ann Oncol; 2002 Aug;13(8):1290-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement.
  • BACKGROUND: The aim of this study was to explore the association between extent of cutaneous involvement, presenting features and progression-free survival (PFS) in patients with primary cutaneous non-Hodgkin's lymphoma (PCNHL) of aggressive histology.
  • METHODS: Previously untreated patients with localized or extensive PCNHL of aggressive histology, treated with combination chemotherapy, but excluding lymphoblastic lymphoma and mycosis fungoides and its variants, were reviewed retrospectively.
  • Median age was 52 years (range 25-81 years), and disease was localized and extensive in 37 and 16 patients, respectively.
  • Twenty-four patients had diffuse large B-cell lymphoma, nine had grade 3 follicular lymphoma, 13 had peripheral T-cell lymphoma (PTCL; not otherwise specified) and seven had anaplastic large cell lymphoma (WHO classification).
  • CONCLUSIONS: PTCL and elevated serum LDH level, but not extent of cutaneous involvement are associated with inferior PFS in aggressive PCNHL treated with combination chemotherapy.

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12181254.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


14. Au WY, Yeung CK, Chan HH, Wong RW, Shek TW: CD30-positive cutaneous T-cell lymphoma with concurrent solid tumour. Br J Dermatol; 2002 Jun;146(6):1091-5
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD30-positive cutaneous T-cell lymphoma with concurrent solid tumour.
  • Extranodal CD30+ T-cell lymphomas seldom carry classical t(2;5) translocation and are usually anaplastic large cell lymphoma kinase protein negative.
  • The prognosis of CD30+ cutaneous T-cell lymphoma (CTCL) is good in the absence of nodal primary or disseminated disease.
  • Although an increased incidence of solid tumours has been reported in patients with CD30+ non-Hodgkin lymphoma of the skin, reports of concurrent malignancies are rare in CD30+ CTCL.
  • The CTCL responded completely to chemotherapy in one patient, who eventually succumbed to gastric cancer.
  • A possible relationship between the lymphoma and the solid tumours is discussed.
  • [MeSH-major] Antigens, CD30 / analysis. Antigens, Neoplasm / analysis. Lymphoma, T-Cell, Cutaneous / immunology. Neoplasms, Multiple Primary / immunology. Skin Neoplasms / immunology. Stomach Neoplasms / immunology. Uterine Neoplasms / immunology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12072086.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antigens, Neoplasm
  •  go-up   go-down


15. Kirova YM, Dumont J, Validire P, Vincent-Salomon A, Decaudin D, Clough CB, Servois V, Savignoni A, Fourquet A: Management of localized primary breast B-cell Non-Hodgkin's Lymphoma: Role of CNS prophylaxis. J Clin Oncol; 2004 Jul 15;22(14_suppl):6722

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of localized primary breast B-cell Non-Hodgkin's Lymphoma: Role of CNS prophylaxis.
  • : 6722 Background:to evaluate the results of combined treatment modality with doxorubicin-based chemotherapy (C), locoregional radiotherapy (RT) and CNS prophylaxis in NHL of the breast.
  • METHODS: From 1984 to 1999, 20 female pts with diffuse large B-cell lymphoma of the breast, were treated at the Curie Institute.
  • The C protocols were: time-modified CHOP: D1, 10, 20,35,50,65 (n=14) or MACOP-B variant (n=3), both with IT MTX and araC.
  • Total dose was 40 Gy in 20-22 fractions using megavoltage photons.
  • RT to CNS (18 Gy/10 fr.) was delivered in the same time.
  • The CR rate was 100% at the end of treatment.
  • Relapses included lymph nodes (3); LN+breast (2); cutaneous (1), GI (1).
  • CONCLUSIONS: CNS prophylaxis by IT C and CNS RT could prevent CNS relapses in pts with primary breast LNH.
  • Though all pts had CR following treatment, relapses occurred in 40% of the pts including late relapses.
  • Prospective studies are needed to improve the long-term results and define the modality of CNS prophylaxis in this rare but aggressive disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014671.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Bonnekoh B, Schulz M, Franke I, Gollnick H: Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab. J Cancer Res Clin Oncol; 2002 Mar;128(3):161-6
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
  • Recently the antibody has been approved for routine administration in primary extracutaneous, treatment-refractory or relapsed low-grade, follicular non-Hodgkin B-cell lymphomas.
  • With regard to the pathogenetically related primary cutaneous lymphomas, the so-called large B-cell lymphoma of the leg represents a distinct, but rare subentity.
  • In an 89-year-old, multimorbid patient who was affected by such a non-resectable CD20+ large B-cell lymphoma limited to the skin of both lower legs, rituximab was used as a first-line monotherapy in order to avoid local or systemic toxicities inevitably linked to conventional treatment modalities, i.e., radio- or chemotherapy.
  • METHODS: Rituximab was administered at a dosage of 375 mg/m(2) i.v. eight times in weekly intervals.
  • RESULTS: The treatment was well tolerated without any adverse reactions, but was accompanied by a mild transient blood eosinophilia.
  • The histologically proven, exophytic, multi-nodular lymphoma showed a substantial regression already at 2 weeks after the onset of the rituximab treatment.
  • At 8 weeks we observed a complete clinical remission which is now stabile for a follow-up period of 6 months without any maintenance therapy.
  • CONCLUSIONS: Our case observation demonstrates that an intensified, i.e. eightfold, rituximab application in weekly intervals may be a highly effective, tumor target cell-specific first-line monotherapy in the management of primary cutaneous large B-cell lymphoma of the leg.
  • Given the rareness of the disease, the result as well as the possible contribution of the prednisolone premedication will have to be evaluated in a future, controlled, multi-centre study.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antineoplastic Agents / pharmacology. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / immunology. Skin Neoplasms / drug therapy. Skin Neoplasms / immunology
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / analysis. Drug Administration Schedule. Humans. Infusions, Intravenous. Leg / pathology. Male. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11935303.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


17. Whittaker SJ, Foss FM: Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev; 2007 Apr;33(2):146-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
  • Primary cutaneous T-cell lymphomas are a heterogenous group of non-Hodgkin lymphomas.
  • The characteristic clinicopathologic and immunophenotypic features and prognoses of the various cutaneous lymphomas have been recently described by the World Health Organization and European Organization for Research and Treatment of Cancer.
  • Cutaneous T-cell lymphoma variants include mycosis fungoides and Sezary syndrome, which are generally associated, respectively, with indolent and aggressive clinical courses and are the subject of this review.
  • Currently utilized treatments for cutaneous T-cell lymphoma include skin-directed therapies (topical agents such as corticosteroids, mechlorethamine, carmustine, and retinoids, phototherapy, superficial radiotherapy, and total skin electron beam therapy), systemic therapies (photophoresis, retinoids, denileukin diftitox, interferons, and chemotherapy), and stem cell transplantation (autologous and allogeneic).
  • This review will describe recent advances in our understanding of the biology (immunologic, cytogenetic, and genetic) of cutaneous T-cell lymphomas and discuss the efficacy and tolerability of the current therapeutic options for cutaneous T-cell lymphomas.
  • Disease progression in over 20% of patients with early stages of disease and the current lack of a definitive treatment which produces durable responses in advanced stages of disease indicates a critical unmet need in CTCL.
  • New insights into the molecular and immunologic changes associated with cutaneous T-cell lymphomas should ultimately lead to the identification of novel therapeutic targets and the development of improved therapeutic options for patients with these malignancies.
  • [MeSH-major] Mycosis Fungoides / therapy. Sezary Syndrome / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Humans. Treatment Outcome


18. Terao H, Kiryu H, Ohshima K, Kikuchi M, Furue M: Cutaneous CD30 (Ki-1)-positive anaplastic large cell lymphoma preceded by Hodgkin's disease. J Dermatol; 2000 Mar;27(3):170-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous CD30 (Ki-1)-positive anaplastic large cell lymphoma preceded by Hodgkin's disease.
  • A 38-year-old female was diagnosed as Hodgkin's disease of the axillar lymph nodes, nodular sclerosis type, as evidenced by the presence of Reed-Sternberg cells positive for CD30 and CD15 and negative for CD3, CD20, and CD45.
  • She achieved complete remission after combination chemotherapy.
  • These findings were mostly compatible with CD30 (Ki-1)-positive anaplastic large cell lymphoma (Ki-1 lymphoma).
  • Our case is considered to be cutaneous Ki-1 lymphoma preceded by Hodgkin's disease.
  • [MeSH-major] Antigens, CD30 / analysis. Antigens, Neoplasm / analysis. Hodgkin Disease / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Axilla. Biopsy. Female. Humans. Lymph Nodes / pathology


19. Régnier-Rosencher E, Barrou B, Marcelin AG, Jacobzone-Leveque C, Cadranel J, Leblond V, Francès C: [Primary effusion lymphoma in two kidney transplant recipients]. Ann Dermatol Venereol; 2010 Apr;137(4):285-9
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary effusion lymphoma in two kidney transplant recipients].
  • [Transliterated title] Lymphome des séreuses chez le transplanté rénal: deux cas.
  • BACKGROUND: Primary effusion lymphoma (PEL) is a highly malignant non-Hodgkin lymphoma associated with Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 infection (KSHV/HHV-8).
  • OBSERVATION: We describe two male kidney transplant recipients, aged 47 and 51 years, followed for Kaposi's sarcoma in skin, lymph nodes, gastrointestinal (GI) tract and lung whose disease was poorly controlled by sirolimus and chemotherapy.
  • Recurrent pleural effusion contrasted with reduction of cutaneous Kaposi lesions.
  • Lymphoma cells were discovered only seven to nine months after the initial effusion despite repeated needle biopsies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Epstein-Barr Virus Infections / etiology. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Immunosuppressive Agents / adverse effects. Kidney Transplantation. Lymphoma, Primary Effusion / etiology. Neoplasms, Multiple Primary / etiology. Postoperative Complications / etiology
  • [MeSH-minor] Digestive System Neoplasms / drug therapy. Digestive System Neoplasms / secondary. Digestive System Neoplasms / virology. Fatal Outcome. Giant Lymph Node Hyperplasia / complications. Giant Lymph Node Hyperplasia / virology. Humans. Immunocompromised Host. Kidney Failure, Chronic / etiology. Kidney Failure, Chronic / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / virology. Lymphatic Metastasis. Male. Middle Aged. Pleural Effusion, Malignant / cytology. Pleural Effusion, Malignant / virology. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / etiology. Sarcoma, Kaposi / virology. Skin Neoplasms / drug therapy. Skin Neoplasms / etiology. Skin Neoplasms / virology. Viral Load

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20417362.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


20. LeMaistre CF: DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications. Clin Lymphoma; 2000 Nov;1 Suppl 1:S37-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The activity of DAB(389)IL-2 in the treatment of cutaneous T-cell lymphoma has established the feasibility of utilizing such a targeted therapeutic in disseminated disease with acceptable toxicity.
  • Data from the phase I trial suggest that the definition of activity in other cancer types, including other non-Hodgkin's lymphomas (NHL), is warranted.
  • Three NHL patients in this study responded, two of whom had follicular lymphomas, with the third having a primary intermediate-grade B-cell NHL that was refractory to chemotherapy and stem cell transplant.
  • This patient has remained in complete remission over 3 years after treatment with DAB(389)IL-2.
  • The need for a threshold level of receptor expression, the difficulty in obtaining representative tissue, the lack of an assay that accurately reflects high-affinity receptor, and the potential difficulty of observer variability in evaluating the assays should point us toward examining response rates in cancer patients where IL-2R cannot be detected or is unknown.
  • Targeting IL-2R-expressing lymphocytes may be an effective strategy for the prevention of graft rejection and to treat or prevent graft-versus-host disease.
  • The potential utility in other autoimmune disorders is unknown, but diseases such as systemic lupus, scleroderma, and vasculitis also may be effective candidates for such ligand fusion therapy.
  • [MeSH-major] Diphtheria Toxin / therapeutic use. Immunosuppressive Agents / therapeutic use. Immunotoxins / therapeutic use. Interleukin-2 / therapeutic use. Recombinant Fusion Proteins / therapeutic use
  • [MeSH-minor] Arthritis, Rheumatoid / drug therapy. Autoimmune Diseases / drug therapy. Clinical Trials as Topic. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, T-Cell, Cutaneous / drug therapy. Psoriasis / drug therapy. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707862.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphtheria Toxin; 0 / Immunosuppressive Agents; 0 / Immunotoxins; 0 / Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox
  • [Number-of-references] 19
  •  go-up   go-down


21. Pinter-Brown LC: SGN-30: a basis for the effective treatment of CD30 positive hematopoietic malignancies. Expert Opin Investig Drugs; 2008 Dec;17(12):1883-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SGN-30: a basis for the effective treatment of CD30 positive hematopoietic malignancies.
  • BACKGROUND: Patients with high-risk, relapsed or refractory Hodgkin lymphoma, those with systemic anaplastic large-cell lymphoma, and those with primary cutaneous CD30-positive disorders are in need of novel therapies.
  • Given the long drug half-life, short infusions may be administered every 2 - 3 weeks.
  • The highest response rate was seen in patients with primary cutaneous CD30-positive lymphoproliferative disease and encouraging results were seen in patients with relapsed or refractory systemic anaplastic large-cell lymphoma.
  • Most responses in Hodgkin lymphoma were stable disease.
  • Despite a majority of patients having had stem cell transplantation, the drug was well tolerated.
  • There are in vivo and in vitro data that SGN-30 may be synergistic with chemotherapy.
  • [MeSH-major] Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / therapeutic use. Antigens, CD30 / immunology. Hematologic Neoplasms / drug therapy. Hematologic Neoplasms / immunology. Immunotherapy
  • [MeSH-minor] Animals. Drug Tolerance. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19012503.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD30; 0 / SGN-30 monoclonal antibody
  • [Number-of-references] 21
  •  go-up   go-down


22. Prunier F, Revel F, Hemery Y, Glaser E, Beaufils P: [Malignant non-Hodgkin's lymphoma presenting with arrhythmia and conduction defects. Report of 2 cases]. Arch Mal Coeur Vaiss; 2000 Nov;93(11):1333-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant non-Hodgkin's lymphoma presenting with arrhythmia and conduction defects. Report of 2 cases].
  • Primary cardiac lymphoma is very rare.
  • The authors report two cases, the first of a 35 year old man in whom primary cardiac lymphoma presented with ventricular tachycardia complicated secondarily by complete atrioventricular block (AVB) with pseudo-inferior wall infarction.
  • The second case was a 37 year old man with a cutaneous T cell lymphoma in whom complete AVB was the first sign of a secondary cardiac localisation of his disease.
  • The finding of cardiac lymphoma should lead to aggressive chemotherapy as soon as possible.
  • [MeSH-major] Heart Block / etiology. Heart Neoplasms / secondary. Lymphoma, Non-Hodgkin / complications. Tachycardia, Ventricular / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11190461.001).
  • [ISSN] 0003-9683
  • [Journal-full-title] Archives des maladies du coeur et des vaisseaux
  • [ISO-abbreviation] Arch Mal Coeur Vaiss
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


23. Scarisbrick JJ, Child F, Spittle M, Calonje E, Russell-Jones R: Systemic Hodgkin's lymphoma in a patient with Sézary syndrome. Br J Dermatol; 2000 Apr;142(4):771-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic Hodgkin's lymphoma in a patient with Sézary syndrome.
  • We report a case of a 71-year-old male with Sézary syndrome diagnosed in 1996 who subsequently developed systemic Hodgkin's lymphoma.
  • His only past treatment was bath psoralen plus ultraviolet A.
  • He has since been treated with multiagent chemotherapy (ChlVPP/PABLOE) which induced a remission in his Hodgkin's disease.
  • Eighteen months later he remains in remission from Hodgkin's disease but the Sézary syndrome remains active.
  • He has also developed a squamous cell carcinoma on the upper lip.
  • Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by a malignant proliferation of CD4-positive cells in the skin and peripheral circulation.
  • Immunosuppression is known to be associated with an increased rate of malignancies and this may account for the occurrence of Hodgkin's disease and squamous cell carcinoma in this patient with Sézary syndrome.
  • [MeSH-major] Carcinoma, Squamous Cell. Hodgkin Disease. Lip Neoplasms. Neoplasms, Multiple Primary. Sezary Syndrome. Skin Neoplasms
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Immune Tolerance / immunology. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Sezary syndrome.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10792230.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


24. Introcaso CE, Kantor J, Porter DL, Junkins-Hopkins JM: Cutaneous Hodgkin's disease. J Am Acad Dermatol; 2008 Feb;58(2):295-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous Hodgkin's disease.
  • Cutaneous Hodgkin's disease is a rare condition that usually occurs late in the course of Hodgkin's lymphoma.
  • This rare condition is thought to have decreased in incidence in recent decades, likely owing to improved treatment of patients with Hodgkin's disease, who are receiving improved chemotherapy and radiation therapy, and the advent of peripheral blood stem cell transplantation.
  • We present the case of a man who developed specific cutaneous Hodgkin's lymphoma 6 months after nonmyeloablative allogenic stem cell transplantation for his recurrent systemic disease.
  • The patient's manifestation of relapse was cutaneous dissemination of the tumor, manifested by erythematous papules and ulcerated nodules.
  • At the time of the cutaneous relapse he had minimal systemic disease.
  • This case illustrates an example of this complication of Hodgkin's disease and stresses the importance of a timely diagnosis to direct appropriate therapy.
  • A review of the literature demonstrates that the patient's lesion morphology and distribution are typical of specific manifestations of cutaneous Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / complications. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18222326.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


25. Madero L, Benito AI, Quintero V, Gonzalez-Vicent M, Díaz MA: Ki-1+ anaplastic large cell lymphoma in a child with unpredictable clinical course. Pediatr Hematol Oncol; 2001 Mar;18(2):143-6
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-1+ anaplastic large cell lymphoma in a child with unpredictable clinical course.
  • Ki-1+ anaplastic large cell lymphoma (Ki-1+ ALCL) is a subtype of non-Hodgkin lymphoma (NHL) with defined histopathological characteristics but with highly variable clinical presentation and outcome.
  • Although in most of the patients the disease behaves as an intermediate- or high-grade lymphoma, some patients present with an indolent clinical course.
  • Factors that determine the clinical behavior of this lymphoma have not yet been identified.
  • A case is reported of a 13-year-old girl who initially presented with Ki-1+ ALCL but later developed recurrent localized cutaneous disease and followed a clinical course similar to that of a low-grade lymphoma.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / pathology. Neoplasm Invasiveness. Neoplasms, Second Primary / chemistry. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / pathology. Recurrence. Skin Neoplasms / chemistry. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11255733.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement